Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GTP-14564||GTP14564|GTP 14564||FLT3 Inhibitor 61 KIT Inhibitor 53 PDGFR-beta Inhibitor 14||GTP-14564 is a selective inhibitor of FLT3, c-Fms, c-Kit, and PDGFR-beta, which may result in reduced downstream signaling and subsequent reductions in cell proliferation and tumor growth (PMID: 12815052).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||hematologic cancer||sensitive||GTP-14564||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing a FLT3 internal tandem duplication were sensitive to GTP-14564 treatment in culture, demonstrating decreased Stat5 activity and growth inhibition (PMID: 12815052).||12815052|
|FLT3 exon 14 ins||acute myeloid leukemia||sensitive||GTP-14564||Preclinical - Cell culture||Actionable||In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to GTP-14564 treatment in culture, demonstrating growth inhibition (PMID: 12815052).||12815052|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|